Ketamine

CHEMBL742 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

237.7 g/mol

LogP

2.2

Phase

4

A dissociative anesthetic used for pain management, sedation, and increasingly for treatment-resistant depression and bipolar disorder. It acts on NMDA receptors in the brain and can produce rapid antidepressant effects in some patients.

Molekularmasse

237,7200 g/mol

LogP

2,20

TPSA

29,10 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Glaucoma Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Obstetrics & Gynecology Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Hypertension Major Depressive Disorder Breast Cancer Gout Chronic Pain Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CNC1(c2ccccc2Cl)CCCCC1=O

InChI

InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3

Molecular Formula

C13H16ClNO

HBD / HBA

1 / 2

Rotierbare Bindungen

2

Schwere Atome

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A dissociative anesthetic used for pain management, sedation, and increasingly for treatment-resistant depression and bipolar disorder. It acts on NMDA receptors in the brain and can produce rapid antidepressant effects in some patients.

Yes, Ketamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL742. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3821. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Ketamine auf PillFYI

Struktur

Schnelldaten

Formel: C13H16ClNO
Synonyme: 6

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.